Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Organogenesis Holdings (ORGO) Enterprise Value (2016 - 2025)

Organogenesis Holdings has reported Enterprise Value over the past 10 years, most recently at -$96.1 million for Q4 2025.

  • Quarterly results put Enterprise Value at -$96.1 million for Q4 2025, up 29.41% from a year ago — trailing twelve months through Dec 2025 was -$96.1 million (up 29.41% YoY), and the annual figure for FY2025 was -$96.1 million, up 29.41%.
  • Enterprise Value for Q4 2025 was -$96.1 million at Organogenesis Holdings, down from -$64.4 million in the prior quarter.
  • Over the last five years, Enterprise Value for ORGO hit a ceiling of -$487000.0 in Q3 2021 and a floor of -$136.2 million in Q4 2024.
  • Median Enterprise Value over the past 5 years was -$95.5 million (2024), compared with a mean of -$84.6 million.
  • Biggest five-year swings in Enterprise Value: plummeted 22080.9% in 2022 and later soared 32.19% in 2025.
  • Organogenesis Holdings' Enterprise Value stood at -$114.5 million in 2021, then increased by 9.81% to -$103.3 million in 2022, then dropped by 1.01% to -$104.3 million in 2023, then crashed by 30.49% to -$136.2 million in 2024, then increased by 29.41% to -$96.1 million in 2025.
  • The last three reported values for Enterprise Value were -$96.1 million (Q4 2025), -$64.4 million (Q3 2025), and -$73.7 million (Q2 2025) per Business Quant data.